BiotechTube
Eidogen-Sertanty

Eidogen-Sertanty

San Diego, United States· Est.
eidogen-sertanty.com
Is this your company? Claim your profile to update info and connect with investors.
Claim profile

Private Company

Total funding raised: $2.5M

Overview

Founded in 2001, Eidogen-Sertanty has established itself as a specialized software and data provider in the AI-driven drug discovery sector. The company's core assets are its curated, large-scale knowledgebases focused on kinases and oncology, complemented by a broader structural bioinformatics platform. It operates a B2B business model, selling its software and data subscriptions to pharmaceutical and biotechnology research organizations. As a private company, it focuses on enabling external R&D rather than developing its own therapeutic pipeline.

Oncology

Technology Platform

The company's platform consists of three core, data-rich software products: 1) Kinase Knowledgebase (KKB): a specialized database for kinase biology with millions of activity data points. 2) Oncology Knowledgebase (OKB): a broader oncology-focused database with target, molecule, and disease model data. 3) Target Informatics Platform (TIP): a structural bioinformatics platform with hundreds of thousands of protein structures and annotated/predicted binding sites. The platforms integrate AI/ML for data aggregation, annotation, and predictive insights to support target assessment and drug design.

Funding History

1
Total raised:$2.5M
Seed$2.5M

Opportunities

The growing adoption of AI and data-driven approaches in pharmaceutical R&D creates a expanding market for specialized discovery tools.
The company's deep, curated knowledgebases in high-value areas like kinases and oncology address a critical need for reliable data, differentiating it from more generalized AI platforms.
The explosion of available protein structural data (e.g., from AlphaFold) increases the potential utility and demand for its Target Informatics Platform.

Risk Factors

Intense competition from well-funded AI drug discovery companies offering broader platform solutions could pressure market share.
The company's curated database model faces disruption risk from next-generation AI models that may generate insights without relying on static, licensed data.
Reliance on pharmaceutical R&D budgets makes the business susceptible to industry downturns or shifts in spending priorities.

Competitive Landscape

Eidogen-Sertanty competes in the AI/ML drug discovery software market against companies like Schrödinger (SDGR), which offers a broad computational platform, and newer AI-native biotechs such as Recursion (RXRX), Exscientia, and Insilico Medicine that develop both platforms and internal pipelines. Its niche focus on deep, curated knowledgebases differentiates it from competitors who may prioritize proprietary AI models or therapeutic development, but it must continually demonstrate superior data depth and utility to maintain its position.

More companies in Digital Health & Biotech SaaS →More companies in United States →